atezolizumab

Overview

Atezolizumab is a humanized IgG1 monoclonal antibody therapy that blocks programmed death-ligand 1 (PD-L1), an immune checkpoint protein expressed on tumor cells and tumor-infiltrating immune cells. Developed by Genentech/Roche and marketed as Tecentriq, it belongs to the class of immune checkpoint inhibitors used in cancer immunotherapy. By binding PD-L1, atezolizumab prevents its engagement of PD-1 on T cells, releasing the inhibitory signal that suppresses cytotoxic T-cell responses within the tumor microenvironment and restoring antitumor immunity. Unlike agents directed at the receptor itself — such as nivolumab and pembrolizumab — atezolizumab targets the ligand, leaving PD-1/PD-L2 interactions intact. It is approved across several solid tumors, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), triple-negative breast cancer, and urothelial carcinoma, and is administered intravenously as well as in a subcutaneous formulation.

In practice, atezolizumab is used both as monotherapy and, more commonly, within combination regimens. Its most established combination pairs it with bevacizumab, an anti-VEGF antibody, as first-line treatment for unresectable HCC — a regimen that displaced sorafenib as standard of care and provides the rationale for pairing checkpoint blockade with antiangiogenic therapy, since VEGF signaling itself contributes to an immunosuppressive tumor microenvironment. It is also combined with cytotoxic chemotherapy such as carboplatin and paclitaxel in lung and breast cancer. Related soluble mediators, including TGF-β1, interleukin-6 (IL-6), and interferon gamma, together with tumor PD-L1 expression and circulating markers such as soluble PD-L1 and cell-free tumor DNA, are actively investigated as determinants of response. As with other checkpoint inhibitors, treatment carries a characteristic spectrum of immune-related adverse events — among them myocarditis, myositis, encephalitis, and endocrinopathies such as fulminant type 1 diabetes — that shape patient selection and monitoring, particularly in patients with underlying liver disease.

Recent Publications Summary

Recent publications on atezolizumab have focused largely on real-world effectiveness, safety, and treatment sequencing in hepatocellular carcinoma (HCC), alongside studies in non-small cell lung cancer (NSCLC), colon cancer, and other malignancies. In a Japanese historical cohort study, unstructured electronic medical records were manually reviewed to reconstruct survival outcomes for patients with NSCLC treated with atezolizumab; among 75 analyzed patients, the median progression-free survival was 3.5 months, illustrating the feasibility of deriving real-world survival data from routine clinical documentation 42489799Jul. Updated randomized data also supported the subcutaneous formulation of atezolizumab in NSCLC, with efficacy, safety, and immunogenicity reported as similar to intravenous administration, while patient preference favored the subcutaneous route 42214243May41946650Apr.

Several recent studies examined atezolizumab-based combinations in unresectable HCC. A multicentre UK cohort of atezolizumab plus bevacizumab reported a median overall survival of 16.5 months, median progression-free survival of 12.3 months, an objective response rate of 42.9%, and adverse events in 41.2% of patients, with grade 3 or higher toxicity in 23.2% 42477572Jul. Other real-world analyses addressed diagnostic pathways, radiologic response assessment, extrahepatic metastatic patterns, long-term survival determinants, and second-line treatment strategies after first-line atezolizumab plus bevacizumab, underscoring ongoing efforts to define which patients benefit most and how best to manage disease progression after this regimen 42213615May42062227Apr42030777Apr41935493Apr42276189Jun42096473May42068971May. safety-focused pharmacovigilance work using FAERS identified distinct adverse-event signals for atezolizumab plus bevacizumab, including fulminant type 1 diabetes mellitus, myositis, encephalitis, and myocarditis, and also noted gastrointestinal haemorrhage and malignant neoplasm progression signals with atezolizumab plus cabozantinib 42461453Jul. A separate case report described pernicious anemia with vitamin B12 deficiency after atezolizumab-containing chemotherapy in a patient with HCC and renal cell carcinoma 42106905May.

Atezolizumab has also been studied in perioperative and adjuvant settings. In resectable non-squamous NSCLC, neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel produced a major pathologic response in 45% of 20 treated patients, with all patients undergoing R0 resection and no grade 5 treatment-related events 42003237Apr. In stage III mismatch repair-deficient colon cancer, a phase III trial compared adjuvant atezolizumab plus mFOLFOX6 followed by atezolizumab monotherapy with mFOLFOX6 alone, enrolling 712 patients in total and reporting a 3-year disease-free survival of 86.3% in the atezolizumab arm at a median follow-up of 40.9 months 41880612Mar. A review of ASCO 2025 gastrointestinal cancer trials also highlighted ATOMIC as practice-changing evidence for adjuvant atezolizumab plus chemotherapy in this setting 41960736Apr.

Beyond lung, liver, and colon cancer, atezolizumab has continued to show activity in selected tumor types and combination strategies. In alveolar soft part sarcoma, three additional years of follow-up from a phase II trial showed a median duration of response of 37.0 months, an objective response rate of 35.8%, and a median progression-free survival of 20.8 months, with better outcomes in ASPSCR1::TFE3 fusion type 1 than type 2 tumors 41999612Apr. In follicular lymphoma, a phase II regimen combining atezolizumab, obinutuzumab, and PET-adapted ultra-low-dose nodal radiotherapy achieved a complete response rate of 93% and an objective response rate of 100%, with 3-year progression-free survival of 80% 41949430Apr. Additional publications described exploratory or preclinical approaches involving PD-L1 targeting, including nanobody-based constructs and bispecific antibodies designed to improve tumor selectivity relative to atezolizumab 42334414Jun41951084Apr.

What Changes, What Holds

1. Real-world and subcutaneous data mainly refine use rather than redefine it
REINFORCES The new NSCLC cohort work and route-comparison data strengthen the practical picture of atezolizumab as an established checkpoint inhibitor whose activity can be tracked outside trials and whose subcutaneous formulation appears to preserve the expected efficacy and safety profile while improving convenience. The historical-record study mainly changes how outcomes can be reconstructed in routine care, not what the drug is understood to do 42489799Jul42214243May.

2. HCC experience now includes more granular effectiveness, sequencing, and safety signals
REINFORCES The recent HCC literature extends the baseline’s account of atezolizumab plus bevacizumab as a standard first-line regimen by showing how it performs in practice, which patients may do better, and what happens after progression. The pharmacovigilance findings add important toxicity detail, but they do not overturn the established benefit-risk framework; they mainly sharpen monitoring for rare immune-mediated harms and bleeding concerns 42477572Jul42461453Jul.

3. Perioperative and adjuvant studies broaden the drug’s role beyond metastatic disease
NEW DIRECTION Neoadjuvant use in resectable NSCLC and adjuvant use in mismatch repair-deficient colon cancer move atezolizumab into curative-intent settings that the Overview does not cover. That does not contradict its checkpoint-blockade mechanism, but it does extend the drug’s understood clinical role from advanced solid tumors into preoperative and postoperative treatment, where durability of benefit and optimal sequencing still need confirmation 42003237Apr41880612Mar.

4. Activity in rare tumors and experimental constructs widens the map without changing the core story
NEW DIRECTION The sarcoma and follicular lymphoma reports show that atezolizumab can contribute to responses in selected nonstandard malignancies, while the nanobody and bispecific-antibody papers point to next-generation PD-L1 targeting strategies rather than changes in atezolizumab itself. These findings sit outside the Overview’s named indications, so they add breadth to the drug’s potential reach but do not displace the established account of how it works 41999612Apr41949430Apr.

Overview update candidates: subcutaneous administration appears comparable to intravenous dosing; real-world HCC data further define outcomes and toxicity for atezolizumab plus bevacizumab; perioperative NSCLC and adjuvant colon cancer uses may merit mention as emerging clinical settings.